Your browser doesn't support javascript.
loading
Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries-An expert consensus statement.
Liew, Adrian; Lydia, Aida; Matawaran, Bien J; Susantitaphong, Paweena; Tran, Huong Thi Bich; Lim, Lee Ling.
Afiliação
  • Liew A; The Kidney & Transplant Practice, Mount Elizabeth Novena Hospital, Singapore, Singapore.
  • Lydia A; Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Dr Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
  • Matawaran BJ; Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Santo Tomas Hospital, Manila, Philippines.
  • Susantitaphong P; Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • Tran HTB; Renal Division, Department of Medicine, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam.
  • Lim LL; Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Nephrology (Carlton) ; 28(8): 415-424, 2023 Aug.
Article em En | MEDLINE | ID: mdl-37153973
ABSTRACT
Recent clinical studies have demonstrated the effectiveness of SGLT-2 inhibitors in reducing the risks of cardiovascular and renal events in both patients with and without type 2 diabetes mellitus. Consequently, many international guidelines have begun advocating for the use of SGLT-2 inhibitors for the purpose of organ protection rather than as simply a glucose-lowering agent. However, despite the consistent clinical benefits and available strong guideline recommendations, the utilization of SGLT-2 inhibitors have been unexpectedly low in many countries, a trend which is much more noticeable in low resource settings. Unfamiliarity with the recent focus in their organ protective role and clinical indications; concerns with potential adverse effects of SGLT-2 inhibitors, including acute kidney injury, genitourinary infections, euglycemic ketoacidosis; and their safety profile in elderly populations have been identified as deterring factors to their more widespread use. This review serves as a practical guide to clinicians managing patients who could benefit from SGLT-2 inhibitors treatment and instill greater confidence in the initiation of these drugs, with the aim of optimizing their utilization rates in high-risk populations.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article